- Home
- EBS vs ALLO Comparison
EBS vs ALLO Comparison
Compare EBS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- ALLO
- Stock Information
- Founded
- EBS 1998
- ALLO 2017
- Country
- EBS United States
- ALLO United States
- Employees
- EBS N/A
- ALLO N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBS Health Care
- ALLO Health Care
- Exchange
- EBS Nasdaq
- ALLO Nasdaq
- Market Cap
- EBS 459.6M
- ALLO 431.9M
- IPO Year
- EBS 2006
- ALLO 2018
- Fundamental
- Price
- EBS $8.09
- ALLO $1.87
- Analyst Decision
- EBS Strong Buy
- ALLO Buy
- Analyst Count
- EBS 2
- ALLO 12
- Target Price
- EBS $14.00
- ALLO $10.06
- AVG Volume (30 Days)
- EBS 999.1K
- ALLO 2.7M
- Earning Date
- EBS 11-06-2024
- ALLO 11-07-2024
- Dividend Yield
- EBS N/A
- ALLO N/A
- EPS Growth
- EBS N/A
- ALLO N/A
- EPS
- EBS N/A
- ALLO N/A
- Revenue
- EBS $1,125,500,000.00
- ALLO $43,000.00
- Revenue This Year
- EBS $6.64
- ALLO N/A
- Revenue Next Year
- EBS $7.95
- ALLO N/A
- P/E Ratio
- EBS N/A
- ALLO N/A
- Revenue Growth
- EBS 2.05
- ALLO 26.47
- 52 Week Low
- EBS $1.42
- ALLO $1.78
- 52 Week High
- EBS $15.10
- ALLO $5.78
- Technical
- Relative Strength Index (RSI)
- EBS 39.08
- ALLO 36.24
- Support Level
- EBS $8.35
- ALLO $1.83
- Resistance Level
- EBS $8.86
- ALLO $2.12
- Average True Range (ATR)
- EBS 0.50
- ALLO 0.16
- MACD
- EBS -0.11
- ALLO -0.02
- Stochastic Oscillator
- EBS 17.58
- ALLO 12.16
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.